Squarepoint
FHTX icon

Squarepoint’s Foghorn Therapeutics FHTX Stock Holding History

Squarepoint’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$496K Sell
103,743
-37,837
-27% -$208K ﹤0.01% 3343
2025
Q4 		$765K Buy
141,580
+104,968
+287% +$476K ﹤0.01% 2841
2025
Q3 		$179K Buy
+36,612
New +$194K ﹤0.01% 3977
2025
Q2 		– Sell
-44,040
Closed -$161K – 4658
2025
Q1 		$161K Buy
+44,040
New +$201K ﹤0.01% 4090

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Squarepoint's FHTX Position: Q1 2026 in Review

Squarepoint reduced its Foghorn Therapeutics (FHTX) stake by 27% in Q1 2026, selling an estimated $208K and leaving 103,743 shares worth $496K. The position accounts for ﹤0.01% of the portfolio, ranked #3343.

Squarepoint first reported a position in FHTX in Q1 2025 and has held it in 4 quarters since. The position peaked at $765K in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Squarepoint held 103,743 shares of Foghorn Therapeutics worth $496K as of Q1 2026.
  • Squarepoint sold 37,837 Foghorn Therapeutics shares in Q1 2026, an estimated $208K.
  • Foghorn Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3343 holding.
  • Squarepoint first reported a position in Foghorn Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Squarepoint's Foghorn Therapeutics position peaked at $765K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.